

Índice

Acknowledgements	1-5
Resumen	7-11
Resum	13-17
Abstract	19-22
Publications	23-28
Abbreviations and Acronyms	29-34

Chapter 1 | General introduction **37-80**

1.1 Molecular recognition	37
1.1.1 <i>Molecular probes</i>	38-39
1.1.2 <i>Nanotechnology</i>	40-41
1.2 Cellular senescence	42-62
1.2.1 <i>Senescence in health and disease</i>	45-49
1.2.2 <i>Senescence induction methods</i>	49-53
1.2.3 <i>Senescence markers</i>	53-58
1.2.4 <i>Senolytics</i>	58-60
1.2.5 <i>Senomorphics</i>	60
1.2.6 <i>The importance of targeting senescent cells</i>	60-62
1.3 Chemical probes for the detection of senescent cells	63-74
1.3.1 <i>SA-β-Gal-dependent chromo-fluorogenic probes</i>	63-69
1.3.2 <i>Other hydrolases probes</i>	70-71
1.3.3 <i>Lipofuscin detection</i>	71-72
1.3.4 <i>Other approaches for the detection of senescent cells using chemical probes</i>	72-74
1.4 Nanodevices targeting senescent cells	75-80

Chapter 2 | Objectives **83**

Chapter 3 | An OFF-ON two-photon fluorescent probe for tracking cell senescence in vivo. **87-113**

3.1 Abstract	88
3.2 Introduction	88-90
3.3 Results and discussion	90-96
3.4 Conclusions	96-97
3.5 Acknowledgments	97
3.6 References	97-99

3.7 Supporting Information	100-113
3.7.1 <i>Materials and methods</i>	100
3.7.2 <i>Synthesis of AH</i>	101-103
3.7.3 <i>Synthesis of AHGa</i>	103-105
3.7.4 <i>Optical studies of AH and AHGa</i>	107-109
3.7.4.1 <i>UV, excitation and fluorescence spectra of AH and AHGa</i>	107-108
3.7.4.2 <i>AH fluorescence changes with pH</i>	108
3.7.4.3 <i>AH and AHGa quantum yield measurements</i>	108-109
3.7.5 <i>In vitro experiments</i>	109-110
3.7.5.1 <i>Cell lines</i>	109
3.7.5.2 <i>Cell viability assays</i>	109-110
3.7.6 <i>In vivo experiments</i>	110-112
3.7.6.1 <i>Mice</i>	110
3.7.6.2 <i>Xenograft assays</i>	111
3.7.6.3 <i>Ex vivo imaging of different sections of fresh organs after AHGa treatment</i>	111-112
3.7.7 <i>References</i>	112-113

Chapter 4 | A two-photon probe based on naphthalimide-styrene fluorophore for the in vivo tracking of cellular senescence **117-156**

4.1 Abstract	118
4.2 Introduction	118-121
4.3 Experimental section	122-125
4.3.1 <i>Materials</i>	122
4.3.2 <i>Hydrolysis reaction</i>	122-123
4.3.3 <i>Cell lines</i>	123
4.3.4 <i>In vitro viability assays.</i>	123
4.3.5 <i>Mouse models.</i>	124-125
4.3.6 <i>Preparation of mouse tumour slices for imaging experiments</i>	125
4.4 Results and discussion	125-135
4.4.1 <i>Synthesis, Characterization, Spectroscopic Features, and Mechanism.</i>	125-127
4.4.2 <i>In Vitro Validation of HeckGal probe.</i>	128-131
4.4.3 <i>In Vivo Validation of HeckGal probe</i>	131-135
4.5 Conclusions	135-136
4.6 Associated content	136
4.7 Acknowledgments	137

4.8 Author contribution	137-138
4.9 References	138-140
4.10 Supporting information	141-156
4.10.1 <i>Table S1. Recently published fluorogenic molecular probes for cellular senescence detection</i>	141
4.10.2 <i>Synthesis of Heck and HeckGal</i>	142-152
4.10.3 <i>Heck fluorescence emission not depends on pH</i>	152
4.10.4 <i>Hydrolysis reaction of Heck-Gal into Heck fluorophore</i>	153
4.10.5 <i>Heck and HeckGal quantum yield measurements</i>	153
4.10.6 <i>In vitro viability assays</i>	154
4.10.7 <i>Emission spectrum of Heck after two-photon excitation</i>	155
4.10.8 <i>Co-staining does not affect to Heck signal</i>	156

Chapter 5 | A renal clearable fluorogenic probe for in vivo detection of cellular senescence **159-198**

5.1 Abstract	160
5.2 Introduction	160-162
5.3 Results and discussion	162-175
5.3.1 <i>Synthesis, spectroscopic characterization, and mechanism studies</i>	162-164
5.3.2 <i>Cy7Gal monitors senescence induction in mouse mammary tumour cells in vitro</i>	164-167
5.3.3 <i>Renal clearance of Cy7 fluorophore allows cell senescence burden evaluation in vivo in a 4T1 breast cancer model treated with senescence-inducing chemotherapy</i>	167-170
5.3.4 <i>In vivo cell senescence burden evaluation in naturally aged BALB/cByJ mice</i>	171-173
5.3.5 <i>In vivo senescence burden evaluation in a senescence-accelerated mouse model</i>	173-175
5.3.6 <i>Cy7Gal is a sensitive and specific probe for senescence burden evaluation regardless of the murine model</i>	175
5.4 Conclusions	175-176
5.5 Acknowledgments	176
5.6 Author Contributions	177
5.7 Competing Interest Statement	177
5.8 Data availability statement	178
5.9 References	178-181
5.10 Supporting information	182-198
5.10.1 <i>Materials</i>	182

5.10.2 Synthesis and characterization of Cy7Gal	182-183
5.10.3 Synthesis and characterization of Cy7	183-184
5.10.4 Synthesis and characterization of WOS-Cy7Gal	185-186
5.10.5 Characterization	186
5.10.6 Hydrolysis of Cy7Gal by human- β Gal	186
5.10.7 Interferents	187
5.10.8 Cell culture	187
5.10.9 Confocal in vitro experiments	187
5.10.10 Competition experiments with D-Galactose	187
5.10.11 Downregulation experiments	188
5.10.12 Western blot analysis of β -galactosidase expression	188
5.10.13 In vitro cytotoxicity studies.	189
5.10.14 Animals	189
5.10.15 In vivo 4T1 breast cancer model treated with senescence-inducing chemotherapy	189
5.10.16 Renal clearance of Cy7Gal	190
5.10.17 Experiments with WOS-Cy7Gal	190-191
5.10.18 Ex vivo IVIS studies	191
5.10.19 Ki67 immunohistochemistry	191
5.10.20 Statistical analyses	191-192
5.10.21 Cy7 and Cy7Gal quantum yield measurements	192
5.10.22 Cy7 fluorescence emission at different pH	192
5.10.23 Hydrolysis of Cy7Gal by human β -Galactosidase and interferents	193
5.10.24 Silencing and western blotting experiments of β -galactosidase	194
5.10.25 X-Gal staining of kidney, liver and tumors from BALB/cByJ female mice carrying orthotopic 4T1 mammary tumors with or without palbociclib treatment	195
5.10.26 Images of BALB/cByJ female mice bearing 4T1 mammary tumors treated with palbociclib and i.p. injected with Cy7Gal	196
5.10.27 Fluorophore biodistribution in BALB/cByJ mice bearing 4T1 mammary tumours treated with palbociclib and in the animal model of accelerated aging SAMP8 and its control SAMR1, after i.p. injection with Cy7Gal or WOS-Cy7Gal	197
5.10.28 Images of 2 and 14 months old BALB/cByJ female mice i.p. injected with Cy7Gal	198

Chapter 6 | Real time in vivo detection of cellular senescence through the controlled release of the NIR fluorescent dye Nile Blue **201-229**

6.1 Abstract	202
6.2 Introduction	202-205
6.3 Results and discussion	205-211
6.3.1 <i>Synthesis, Characterization, Spectroscopic Features and Mechanism</i>	205
6.3.2 <i>In vitro validation</i>	207-208
6.3.3 <i>In vivo validation</i>	208-211
6.4 Conclusions	211-212
6.5 Acknowledgements	212
6.6 References	213-214
6.7 Supporting information	215-229
6.7.1 <i>Materials and methods</i>	215-216
6.7.2 <i>Synthesis of materials</i>	216-217
6.7.3 <i>Materials characterization</i>	218-223
6.7.4 <i>Calculations of loaded and released NB</i>	223-224
6.7.5 <i>Cargo release experiments</i>	224
6.7.6 <i>In vitro studies</i>	224-226
6.7.7 <i>In vivo studies</i>	226-227
6.7.8 <i>Immunohistochemistry protocol</i>	227
6.7.9 <i>Biodistribution experimental protocol</i>	228
6.7.10 <i>Toxicity and pro-inflammatory factors in vivo evaluation of S3</i>	229

Chapter 7 | Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity **233-281**

7.1 Abstract	234
7.2 Introduction	235-238
7.3 Results	239-254
7.3.1 <i>Synthesis, characterisation and hydrolysis reaction studies</i>	239-240
7.3.2 <i>Nav-gal is a prodrug with effective wide-ranging senolytic activity that depends on GLB1 activity</i>	240-245
7.3.3 <i>Nav-gal induces apoptosis of senescent cells while preserving viability of nonsenescent cells</i>	245-246

7.3.4 Cisplatin and Nav-gal have additive antitumour effects when used concurrently and sequentially	246-249
7.3.5 Therapeutic activity of Nav-gal in xenografts and orthotopic models of NSCLC	249-251
7.3.6 Nav-gal has reduced platelet toxicity when compared with Navitoclax	252-255
7.4 Discussion	255-259
7.5 Experimental procedures	260-269
7.5.1 Synthesis, characterisation and hydrolysis reaction studies	260
7.5.2 Characterisation of Nav-gal prodrug	260-261
7.5.3 Hydrolysis reaction of Nav-gal studies	261
7.5.4 Cells and reagents	261-262
7.5.5 GLB1 downregulation	262
7.5.6 Cell viability and apoptosis analysis	263
7.5.7 Clonogenic assay	264-265
7.5.8 Immunoblotting	265
7.5.9 Mouse experiments	265-266
7.5.10 Histology	267
7.5.11 Platelet apoptosis analysis	268
7.5.12 Statistical analysis	268-269
7.6 Acknowledgments	269
7.7 Conflict of interests	270
7.8 Author contributions	270-271
7.9 Data availability statement	271
7.10 References	271-273
7.11 Supporting Information	274-281
<i>Figure S1. Molecular characterisation of pro-drug Nav-gal.</i>	274-275
<i>Figure S2. Assessment of the induction of cellular senescence in cell lines used for in vitro experiments</i>	276
<i>Figure S3. The galacto-conjugated pro-drug Nav-gal shows a lower induction of apoptosis of nonsenescent melanoma SK-Mel-103 cells and lung cancer A549 cells, and significantly decreases clonogenic potential in combination with cisplatin</i>	277-278
<i>Figure S4. Sequential Nav-gal treatment after chemotherapy Decreases tumour volume and platelet toxicity compared to Navitoclax.</i>	279
<i>Figure S5. Concomitant treatment of lung tumours with pro-drug Nav-Gal and cisplatin significantly decreases tumour burden in an orthotopic lung cancer mouse model.</i>	280-281

Figure S6. Gating strategy for the analysis of Annexin V-positive platelets (apoptotic platelets) in samples from human and mouse blood.

281

Chapter 8 | Conclusions and Perspectives

285-288

